Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

Medicare covers lupus treatment in different ways depending on your age and how the condition affects you. Read more.

In a small phase II trial of cutaneous lupus erythematosus (CLE), patients treated with the TYK2 inhibitor had as much as 50% improvement in disease status at week 16. Adverse events in both ...

Cutaneous vasculitis (CV) is a term used for inflammation of the blood vessels in the skin that occurs in up to 70% of patients with lupus erythematosus (LE). The inflammation affects the smaller ...

The company reported positive phase 2 data from the cohort of cutaneous lupus erythematosus (CLE) patients late last year. Thursday, Merck revealed the systemic lupus erythematosus (SLE ...

standard therapy alone, according to data. ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter ...

The foregoing results lead to the conclusion that patients with disseminated lupus erythematosus and some patients with rheumatoid arthritis present a delayed cutaneous hypersensitivity when ...

Extra-cutaneous symptoms that suggest systemic ... The patient is a 47-year-old male with a 6-year history of systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome.

Lupus is an autoimmune disease where the body’s immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new study co-led by the University of Zurich has now shown ...

Systemic lupus erythematosus, or lupus, is a complex autoimmune disease ... particularly promising led to visible improvements in a clinical study in patients with cutaneous lupus after just two weeks ...